ArticleTranslational oncology2026
L-type calcium channel-mediated lipid metabolic reprogramming in gastric adenocarcinoma progression.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundl-type calcium channels (LTCCs) play an important role in tumorigenesis, but their expression profile, functional significance, and therapeutic potential in gastric adenocarcinoma (GAC) remain unclear. Concurrently, aberrant lipid metabolism is widely acknowledged as a key driver of GAC progression, but its upstream regulatory mechanisms have yet to be fully elucidated. This study was designed to explore the association between LTCCs and lipid metabolic reprogramming in GAC and to investigate its influence on GAC progression and clinical outcomes.
methodsThe expression profiles of LTCCs family members in GAC were analyzed using the TCGA database. Gastric cancer cells were treated with the LTCCs antagonist (+)-Bay-K-8644, and its effect on the malignant phenotype of the cells was detected by CCK-8, clone formation, scratch healing and transwell assay. Metabolic changes were analyzed by UPLC-Q-TOF-MS metabolomics. The role of lipid metabolism in the regulation of LTCCs was verified by palmitic acid (PA) backfill assay.
resultsBioinformatics analysis showed that Voltage-dependent LTCCs subunit alpha-1D (CACNA1D) was up-regulated in GAC. CACNA1D had excellent diagnostic value and its high expression was associated with poor prognosis. (+)-Bay-K-8644 significantly inhibited gastric cancer cells' proliferation, clone formation, and migration ability. Metabolomics analysis revealed that (+)-Bay-K-8644 treatment resulted in reprogramming of lipid metabolism. Exogenous PA was able to partially reverse the anticancer effects of (+)-Bay-K-8644 and restore cell proliferation and migration.
conclusionsThis study elucidated the unique expression pattern of LTCCs in GAC for the first time, and confirmed that LTCCs antagonism exerts anticancer effects by inducing reprogramming of lipid metabolism. These findings provide a theoretical basis for repositioning calcium channel blockers for GAC therapy and suggest that combined targeting of calcium channels and lipid metabolism may become a new strategy for GAC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.